Cargando…

Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer

SIMPLE SUMMARY: Metastatic castration-resistant prostate cancer (mCRPC) is the most aggressive and deadly form of prostate cancer. As a bone-predominant metastatic disease, liquid biopsy-based biomarkers have advantages in monitoring cancer dynamics. Previous studies have demonstrated the associatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Chun, Zhang, Zhenchao, Chong, Weelic, Luo, Rui, Myers, Ronald E., Gu, Jian, Lin, Jianqing, Wei, Qiang, Li, Bingshan, Rebbeck, Timothy R., Lu-Yao, Grace, Kelly, William K., Yang, Hushan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828213/ https://www.ncbi.nlm.nih.gov/pubmed/33450815 http://dx.doi.org/10.3390/cancers13020268

Ejemplares similares

Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients
por: Chong, Weelic, et al.
Publicado: (2021)

Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism
por: Abu-Khalaf, Maysa, et al.
Publicado: (2022)

Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer
por: Luo, Rui, et al.
Publicado: (2021)

Treatment Stratification of Patients with Metastatic Castration-Resistant Prostate Cancer by Machine Learning
por: Deng, Kaiwen, et al.
Publicado: (2019)

Network-based stratification analysis of 13 major cancer types using mutations in panels of cancer genes
por: Zhong, Xue, et al.
Publicado: (2015)

A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
por: Lin, Jianqing, et al.
Publicado: (2016)

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
por: van der Zande, Kim, et al.
Publicado: (2021)

Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer
por: Lin, Hui-Ming, et al.
Publicado: (2021)

Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
por: Groen, Levi, et al.
Publicado: (2023)

Characterizing Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles in Metastatic Castration-Naive and Castration-Resistant Prostate Cancer Patients
por: Isebia, Khrystany T., et al.
Publicado: (2022)

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
por: de Kruijff, Ingeborg E., et al.
Publicado: (2019)

Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
por: Magbanua, Mark Jesus M, et al.
Publicado: (2012)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2021)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
por: Chong, Julio T, et al.
Publicado: (2018)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer
por: Gerdtsson, Anna S., et al.
Publicado: (2021)

Association of Circulating Tumor Cells with Inflammatory and Biomarkers in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer
por: Theil, Gerit, et al.
Publicado: (2021)

Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T
por: Hawley, Jessica E, et al.
Publicado: (2021)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer
por: Isebia, Khrystany T., et al.
Publicado: (2023)

Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer
por: Sobhani, Navid, et al.
Publicado: (2020)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
por: Zaitsu, Masayoshi, et al.
Publicado: (2012)

Comparison of metastatic castration-resistant prostate cancer in bone with other sites: clinical characteristics, molecular features and immune status
por: Xu, Zhengquan, et al.
Publicado: (2021)

Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection
por: Li, Ling, et al.
Publicado: (2016)

Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians
por: Sureka, Sanjoy Kumar, et al.
Publicado: (2016)

Update on options for treatment of metastatic castration-resistant prostate cancer
por: Vishnu, Prakash, et al.
Publicado: (2010)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2016)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Denosumab-induced hypocalcaemia in metastatic castrate-resistant prostate cancer
por: Gunawan, Florence, et al.
Publicado: (2019)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
por: Bansal, Dhruv, et al.
Publicado: (2021)

Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
por: Rathi, Nityam, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1ub43sqh3ltfugqak0dddbcn16